Consumer Commission Fines BigMuscles Nutrition For Misleading Health Claims

Mumbai: The consumer commission in Mumbai has deemed BigMuscles Nutrition guilty of service deficiency for using ‘unknown’ amino acids to boost protein content in one of its health supplements. This practice, known as protein-spiking, has raised serious health concerns.

The District Consumer Disputes Redressal Commission’s July 15 order stated that consumption of such products posed health risks, ranging from short-term side effects like headaches and nausea to long-term issues like liver damage and heart problems.

BigMuscles Nutrition was ordered to pay Rs 36,409 to the complainant for the product cost and lab testing. The commission also criticized the company for making false claims about their product and continuing misleading practices.

Related Posts

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Bengaluru: The Central Council for Research in Ayurvedic Sciences (CCRAS) has called for stronger scientific evidence, safety monitoring and translation of research into market-ready technologies to improve the credibility and…

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

The Team Meticulously averted the Risk of Thrombosis, Husband was Donor Delhi/NCR : Doctors at Yashoda Medicity have successfully performed a high-risk kidney transplant in a 28-year-old woman with Antiphospholipid…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Ayurveda needs stronger evidence, safety monitoring for market adoption, says CCRAS

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Yashoda Medicity Successfully Performs High-Risk Kidney Transplant in 28-Year- Old Woman

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

Avacta delivers two clinical stage peptide-drug conjugates to target delivery of toxic payloads into the tumour microenvironment

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

US FDA approves first gene therapy for paediatric patients with Sanfilippo syndrome type A

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Technology and accessibility are key to growth of advanced treatment of heart diseases, says expert

Puresta launches EVERQ, AI-powered skin-health platform

Puresta launches EVERQ, AI-powered skin-health platform